Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Global Market

6.16USD
17 Aug 2018
Change (% chg)

$0.01 (+0.16%)
Prev Close
$6.15
Open
$6.15
Day's High
$6.30
Day's Low
$6.09
Volume
13,951
Avg. Vol
48,025
52-wk High
$11.47
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Redhill Biopharma Q4 Basic Loss Per Ordinary Share $0.05
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Redhill Biopharma Ltd ::Q4 REVENUE ROSE 31 PERCENT TO $2.0 MILLION.QTRLY BASIC LOSS PER ORDINARY SHARE $0.05.CASH BALANCE AS OF DECEMBER 31, 2017 WAS $46.2 MILLION, A DECREASE OF $20 MILLION, COMPARED TO $66.2 MILLION AS OF DECEMBER 31, 2016.  Full Article

Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D
Tuesday, 16 Jan 2018 08:00am EST 

Jan 16 (Reuters) - Redhill Biopharma Ltd ::REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDA® FOR IBS-D.REDHILL BIOPHARMA - INDEPENDENT REVIEW & ANALYSIS OF FINAL RESULTS CONFIRMED THAT PHASE II STUDY WITH BEKINDA 12 MG SUCCESSFULLY MET PRIMARY ENDPOINT.REDHILL BIOPHARMA - PLANS TO MEET WITH FDA IN H1 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D.  Full Article

Redhill Biopharma provides 2017 year-end business update
Tuesday, 5 Dec 2017 09:30am EST 

Dec 5 (Reuters) - Redhill Biopharma Ltd ::REDHILL BIOPHARMA PROVIDES 2017 YEAR-END BUSINESS UPDATE.REDHILL BIOPHARMA LTD - ‍COST REDUCTION PLAN IS IN PLACE TO GRADUALLY REDUCE AVERAGE QUARTERLY CASH BURN RATE IN 2018 TO APPROXIMATELY $8.5 MILLION​.REDHILL BIOPHARMA LTD - FOCUSING ON DELIVERING PHASE III DATA READ-OUTS WITH RHB-104 FOR CROHN'S DISEASE AND TALICIA FOR H. PYLORI INFECTION.  Full Article

Redhill biopharma Q3 ‍loss per ordinary share US$0.09
Monday, 13 Nov 2017 07:30am EST 

Nov 13 (Reuters) - Redhill Biopharma Ltd :Redhill Biopharma reports 2017 third quarter financial results.Q3 revenue $1.5 million.Redhill Biopharma Ltd - ‍decrease quarterly cash burn rate and continued revenue growth are expected in 2018​.Redhill Biopharma Ltd - ‍top-line results from first Phase III study with RHB-104 for Crohn's disease (MAP US study) expected in mid-2018​.Redhill Biopharma - ‍top-line results from confirmatory Phase III study with Talicia (RHB-105) for treatment of H. Pylori infection, expected in H2/2018​.Redhill Biopharma Ltd qtrly ‍loss per ordinary share us$0.09​.  Full Article

RedHill Biopharma prices public offering of its American Depositary Shares
Wednesday, 8 Nov 2017 09:13am EST 

Nov 8 (Reuters) - Redhill Biopharma Ltd : :RedHill Biopharma prices public offering of its American Depositary Shares.RedHill Biopharma Ltd - ‍pricing of its underwritten public offering for a total number of 4.1 million ADSS at a public offering price of $5.50 per ADS​.  Full Article

Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Redhill Biopharma Ltd ::Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines.Redhill Biopharma Ltd - ‍PDUFA date is expected to be set by FDA for first half of 2018 for Rizaport​.  Full Article

IntelGenx and Redhill Biopharma resubmit Rizaport NDA to FDA
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - IntelGenx Technologies Corp :Intelgenx and Redhill Biopharma resubmit Rizaport new drug application to the FDA.Intelgenx Technologies Corp- ‍co, Redhill Biopharma have resubmitted new drug application to U.S. FDA for Rizaport 10 mg​.Intelgenx-‍if Rizaport NDA resubmission is complete & permitted a full review by FDA, PDUFA date is expected to be set by agency for first half of 2018​.  Full Article

RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104
Monday, 23 Oct 2017 07:00am EDT 

Oct 23 (Reuters) - Redhill Biopharma Ltd :RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104.RedHill Biopharma - ‍enrollment in phase III study with RHB-104 for Crohn's Disease to be completed in Nov 2017, top-line results expected in Q3/2018​.RedHill Biopharma Ltd - ‍new patent, covering RHB-104 for relapsing-remitting multiple sclerosis (MS), is expected to be valid until 2032, once granted​.  Full Article

RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer
Friday, 20 Oct 2017 07:00am EDT 

Oct 20 (Reuters) - Redhill Biopharma Ltd :RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer.RedHill Biopharma says it ‍is also evaluating utilization of MESUPRON in several inflammatory gastrointestinal indications​.  Full Article

Redhill Biopharma announces positive results from phase 2 study of Bekinda in patients with irritable bowel syndrome (IBS-D)
Tuesday, 3 Oct 2017 07:00am EDT 

Oct 3 (Reuters) - Redhill Biopharma Ltd : :Redhill Biopharma announces positive top-line results from phase II study of bekinda® in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).Redhill Biopharma Ltd - ‍Bekinda®(i) 12 mg phase II study successfully met its primary endpoint​.Redhill Biopharma- intends to pursue phase III studies with bekinda 12 mg, plans to meet with FDA by early 2018.Redhill Biopharma Ltd says ‍bekinda 12 mg was also shown to be safe and well tolerated​.Redhill-After successful first phase 3 study, positive guidance meeting with FDA, co designing confirmatory phase 3 study to support NDA for Bekinda 24​.Redhill Biopharma Ltd - ‍completion of clinical study report expected in Q1 of 2018​.  Full Article

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

No consensus analysis data available.